ConductScience.org, home

Paper40939764

Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.

Okereke LC and 3 others. Math Biosci, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control. Papers, record 40939764. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40939764

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.
PubMed
Journal
Math Biosci
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-24
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Okereke LCLois C
2Lima EABFErnesto A B F
3Sorace AGAnna G
4Yankeelov TEThomas E

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neurotoxicity SyndromesMajor topic
NeoplasmsMajor topic
Antineoplastic AgentsMajor topic
Tumor Burden
Humans
Computer Simulation
Treatment Interruption
Precision Medicine

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA240589NCI NIH HHSUnited StatesR01CA240589PubMedNIH RePORTER
R01 CA276540NCI NIH HHSUnited StatesR01CA276540PubMedNIH RePORTER
U01 CA253540NCI NIH HHSUnited StatesU01CA253540PubMedNIH RePORTER

Download CSV of grants

References99

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112894998Molecular mechanisms of chemotherapy-induced hair loss.J Investig Dermatol Symp Proc2003https://conductscience.org/library/papers/12894998PubMed
223850479Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.J Theor Biol2013https://conductscience.org/library/papers/23850479PubMed
325445718The double-edged sword: Neurotoxicity of chemotherapy.Blood Rev2015https://conductscience.org/library/papers/25445718PubMed
416322118Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.Ann Oncol2006https://conductscience.org/library/papers/16322118PubMed
526775862Dynamics and control of a mathematical model for metronomic chemotherapy.Math Biosci Eng2015https://conductscience.org/library/papers/26775862PubMed
619097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
732143730A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer.Trials2020https://conductscience.org/library/papers/32143730PubMed
833434599The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy.J Control Release2021https://conductscience.org/library/papers/33434599PubMed
927864095Optimization of an in vitro chemotherapy to avoid resistant tumours.J Theor Biol2017https://conductscience.org/library/papers/27864095PubMed
1033239688Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer.Sci Rep2020https://conductscience.org/library/papers/33239688PubMed
1131619372Embracing the complexity: Older adults with cancer-related cognitive decline-A Young International Society of Geriatric Oncology position paper.J Geriatr Oncol2020https://conductscience.org/library/papers/31619372PubMed
1215958110Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.Intern Med J2005https://conductscience.org/library/papers/15958110PubMed
1328802891Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.Clin Lymphoma Myeloma Leuk2017https://conductscience.org/library/papers/28802891PubMed
1435776787Measuring competitive exclusion in non-small cell lung cancer.Sci Adv2022https://conductscience.org/library/papers/35776787PubMed
1529148865Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.Pediatr Hematol Oncol2017https://conductscience.org/library/papers/29148865PubMed
1636699654Cancer treatment induces neuroinflammation and behavioral deficits in mice.Front Behav Neurosci2022https://conductscience.org/library/papers/36699654PubMed
1735557664The 18-kDa Translocator Protein PET Tracers as a Diagnostic Marker for Neuroinflammation: Development and Current Standing.ACS Omega2022https://conductscience.org/library/papers/35557664PubMed
1824889111Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases.Nat Commun2014https://conductscience.org/library/papers/24889111PubMed
1923666914Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.Ann Oncol2013https://conductscience.org/library/papers/23666914PubMed
2028209166Intra-tumor heterogeneity from a cancer stem cell perspective.Mol Cancer2017https://conductscience.org/library/papers/28209166PubMed

See all 99 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40939764

GET https://conductscience.org/api/papers/v1/40939764/references?page=2